SCHEMBL69697

SCHEMBL69697

C=CCc1ccc(O)cc1O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TYR P14679 6/20 0.58
GABRA1 P14867 3/20 0.53
GABRB2 P47870 3/20 0.53
ALOX5 P09917 2/20 0.47
POLB P06746 1/20 0.46
XDH P47989 1/20 0.45
MEN1 O00255 3/20 0.44
MAPT P10636 3/20 0.44
KMT2A Q03164 3/20 0.44
TP53 P04637 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
ALDH2 P05091 1/20 0.44
GAA P10253 1/20 0.44
AKR1B1 P15121 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1906438 0.92 TYR (0.50) TYRGABRA1GABRB2ALOX5POLB
SCHEMBL4446113 0.84 GABRA1 (0.50) TYRGABRA1GABRB2ALOX5POLB
SCHEMBL9640862 0.83 ESR1 (0.49) TYRGABRA1GABRB2POLBXDH
SCHEMBL30893166 0.83 GABRA1 (0.70) TYRGABRA1GABRB2ALOX5POLB
SCHEMBL71514 0.83 GABRA1 (0.70) TYRGABRA1GABRB2ALOX5POLB
SCHEMBL9296359 0.81 GABRA1 (0.47) TYRGABRA1GABRB2ALOX5POLB
SCHEMBL1006107 0.81 XDH (0.70) GABRA1GABRB2ALOX5POLBXDH
SCHEMBL8259600 0.81 GABRA1 (0.52) GABRA1GABRB2ALOX5POLBXDH
SCHEMBL3749697 0.80 TYR (0.60) TYRALOX5MEN1MAPTKMT2A
SCHEMBL11115074 0.79 GABRA1 (0.46) TYRGABRA1GABRB2ALOX5POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024099689-A1 A PERSONAL CARE COMPOSITION UNILEVER IP HOLDINGS B.V. (NL) 2024-05-16 WO claimed
CN-114767562-B Topical skin lightening additives and compositions with amino acids and nicotinamide compounds 联合利华知识产权控股有限公司 2024-05-10 CN claimed
EP-3558245-B1 TOPICAL SKIN LIGHTENING ADDITIVE AND COMPOSITION WITH AMINO ACIDS AND PPAR ACTIVATING FATTY ACIDS UNILEVER IP HOLDINGS B V (NL) 2024-02-07 EP claimed
CN-115594896-B Rubber composition, rubber product and application 北京彤程创展科技有限公司 2023-11-21 CN claimed
EP-4188309-B1 COSMETIC MASK FOR IMPROVING APPEARANCE OF SKIN UNILEVER IP HOLDINGS B V (NL) 2023-11-01 EP claimed
EP-3335694-B1 MELANOGENESIS INHIBITOR TAKASAGO PERFUMERY CO LTD (JP) 2023-09-27 EP claimed
US-20230240967-A1 COSMETIC MASK FOR IMPROVING APPEARANCE OF SKIN CONOPCO, INC., D/B/A UNILEVER (US) 2023-08-03 US claimed
EP-3708148-B1 MELANOGENESIS INHIBITOR COMPRISING D-PANTOTHENYL ALCOHOL, AND SKIN-WHITENING COSMETIC CONTAINING SAME MELANOGENESIS INHIBITOR POLA CHEM IND INC (JP) 2023-07-19 EP claimed
EP-4188309-A1 COSMETIC MASK FOR IMPROVING APPEARANCE OF SKIN Unilever IP Holdings B.V. (NL) 2023-06-07 EP claimed
CN-116217754-A 4-alkyl resorcinol cyclodextrin derivative supermolecule, preparation method thereof and application thereof in preparing cosmetics 上海贤鼎生物科技有限公司 2023-06-06 CN claimed
US-20080260878-A1 Topical; adenosine 5'-monophosphates and salts thereof; arbutins, ellagic acid, 4-alkylresorcinols, linolic acid, tranexamic acid, chamomile extracts, ubiquinones; chloasma, freckles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-10-23 US claimed
WO-2007110415-A2 USE OF DIACETYL TRIMERS AND COSMETIC OR THERAPEUTIC FORMULATIONS CONTAINING THESE COMPOUNDS SYMRISE GMBH & CO. KG (DE) 2007-10-04 WO claimed
EP-1806120-A1 COMPOSITION FOR PREVENTION OR ALLEVIATION OF PIGMENTATION Otsuka Pharmaceutical Company, Limited (JP) 2007-07-11 EP claimed
US-20060129002-A1 Process for the synthesis of alkylresorcinols HONEYWELL INTERNATIONAL INC. 2006-06-15 US claimed
WO-2004052827-A1 PROCESS FOR THE PREPARATION OF 4-ALKYL RESORCINOL ESTERS UNILEVER PLC (GB) 2004-06-24 WO claimed
EP-0703780-A4 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE UNIV SYDNEY (AU) 1998-01-07 EP claimed
CN-1124922-A Use of natural products and related synthetic compounds for the treatment of cardiovascular diseases UNIV SYDNEY (AU) 1996-06-19 CN claimed
EP-0703780-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1996-04-03 EP claimed
WO-1994028886-A1 USE OF NATURAL PRODUCTS AND RELATED SYNTHETIC COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE THE UNIVERSITY OF SYDNEY (AU) 1994-12-22 WO claimed
US-4086281-A ACID CATALYST KOPPERS COMPANY, INC. (US) 1978-04-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060129002-A1 Process for the synthesis of alkylresorcinols ACSL4, ZDHHC20, ACSL6 TYR 2177/4885GABRA1 2595/4885GABRB2 3078/4885
US-20230240967-A1 COSMETIC MASK FOR IMPROVING APPEARANCE OF SKIN POT1, TERT, CUTA TYR 159/4885GABRA1 2253/4885GABRB2 3418/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.